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Summary
QUESTIONS UNDER STUDY: Although the ethical and
health implications of neuroenhancement have been in-
tensely discussed over the past years, little is known about
the experiences and attitudes of physicians confronted with
requests for neuroenhancing substances. The aim of this
study was to explore general practitioners’ and psychiat-
rists’ familiarity with such requests and their willingness to
prescribe these products.
METHOD: A nation-wide cross-sectional survey among
general practitioners and psychiatrists in Switzerland was
conducted. A questionnaire was developed, pre-tested and
sent out to a pre-defined sample of 1,600 Swiss practising
physicians in the fields of psychiatry and general practice/
internal medicine in the German-speaking and French-
speaking part of Switzerland.
RESULTS: A total of 393 questionnaires were returned
(response rate: 24.7%). 80.2% of study participants were
encountered requests for neuroenhancing products in their
own practice, mostly not exceeding 1–2 times a year. A
total of 41.1% were undecided when asked if they categor-
ically against neuroenhancement, 49% would decide on a
case-by-case basis, and 9.6% would decide according to
patients’ wishes.
CONCLUSIONS: Swiss psychiatrists and general practi-
tioners are confronted with requests for neuroenhancement,
albeit not very frequently. Most participants embrace a
pragmatic position towards neuroenhancement, although
there is also a considerable degree of uncertainty about the
appropriateness of a categorical refusal. A minority would
follow a consumer model that leaves the decision about the
use of neuroenhancers to the client, even though this con-
flicts with legal requirements regarding drug prescriptions.
Key words: neuroenhancement; ethics; survey;
physicians; attitudes
Introduction
Neuroenhancement – in the sense of improving cognitive
and emotional capacities through pharmacological sub-
stances in healthy humans – is an intensely discussed topic
in medical ethics [1–5]. Issues at stake in the debate about
neuroenhancement (NE) are the autonomy of users and the
moral impetus to develop our full human potential versus
concerns about justice, solidarity in an increasingly com-
petitive and demanding society, and safety. The latter is
of particular concern given that long-term side effects of
available putative neuroenhancers such as methylphenidate
and modafinil have not yet been investigated in healthy hu-
mans [1].
At the same time there are few empirical data on (potential)
users [6–10] and even less on (potential) providers [4, 11,
12]. Some recent studies have investigated the perspectives
of physicians from the US [4] and from Canada and the
US [12], but to date there are no corresponding data on
Switzerland. Although it is often claimed in the media that
there is an epidemic of neuroenhancing drug use, we do not
know how frequently physicians actually encounter such
requests and how they deal with them. Certainly not all
neuroenhancers will be obtained through physicians. Still,
taking into account the perceptions and perspectives of
physicians, who are potentially confronted with requests
for neuroenhancers in their daily work and who need to
make decisions on whether or not to prescribe the respect-
ive drug, is of key relevance to a debate that is not supposed
to be purely theoretical but based on clinical realities.
The aim of this study was to explore general practitioners’
and psychiatrists’ attitudes towards NE, their familiarity
with requests for such products as well as their willingness
to prescribe them.
Methods
Development of the questionnaire
In preparation of the questionnaire eight qualitative, half-
standardised interviews were conducted. Four practising
psychiatrists and four general practitioners in the region of
Zurich were interviewed. The interviews aimed to obtain a
sense of the degree of physicians’ familiarity with NE and
to explore ways to frame items and possible answers so that
they would make sense to participants. The interviews were
transcribed and analysed with the Software MaxQda2 for
Windows programme (Berlin-Marburg-Amöneburg, Ger-
many; see www.maxqda.com), using the method of induct-
ive formation of categories according to Mayring [13]. The
results were incorporated into the development of items for
the pilot questionnaire, which was sent to 48 randomly se-
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lected persons from the main sample. The feedback and
the results of the ten returned questionnaires (20.8%) were
used to produce the final version of the questionnaire.
The procedures of the survey were in accordance with the
ethical standards of a research ethics committee and with
the Helsinki declaration.
Questionnaire
The questionnaire starts with demographic data as well as
questions about the term “neuroenhancement” (the Ger-
man or French questionnaires can be made available by the
authors upon request). The following items address par-
ticipants’ concepts of disease and treatment. After these
initial questions a definition of the term “neuroenhance-
ment” is presented, to which the remainder of the question-
naire refers: “Neuroenhancement stands for the improve-
ment (‘optimisation’) of cognitive and emotional abilities
of healthy humans through pharmacological substances.
The most discussed substances are methylphenidate (Rital-
in©), modafinil (Modasomil©, Provigil©), antidepressants
and anti-dementia drugs, although with different clinical
effectiveness [7, 14]. There are also some additional sub-
stances, which are potential therapeutic agents for diseases,
and which are still in the experimental phase.” The subse-
quent part of the questionnaire contains four case scenarios,
which were chosen to represent clinically relevant requests
for the most frequently used neuroenhancing products:
1. A student will soon take his two last and decisive
exams. If he is successful, he will obtain his degree and a
well-paid position. If not, he cannot proceed with his stud-
ies and will have to leave the university. He has already
had to repeat some exams, due to difficult personal circum-
stances. After a time of intense exam preparations, he asks
his doctor for a drug to diminish his need for sleep so that
he can use the scarce remaining time as efficiently as pos-
sible.
2. For several weeks, a single mother-of-two has cared
for her terminally ill mother at home and has become com-
pletely exhausted. However, she does not want to place her
mother in a care institution because she expects that she
will not live much longer. The mother had supported her
during her divorce and she would like to return the favour.
She asks her physician for a stimulant so she can keep up
with her workload for a longer time.
3. A 24 year-old woman, who is shy and has low self-
esteem around men wants to get rid of her inhibitions. She
asks her physician for a drug that can reduce her anxiety. A
female friend of hers is taking a drug for social phobia, and
she would also like to try this drug.
4. A renowned scientist, who has just come back from
a business trip, is suffering from jet lag and wants a pre-
scription for modafinil as he wants to be back at his normal
performance level as soon as possible, as he is attending a
conference in the near future. He asks his family doctor to
prescribe an appropriate stimulant.
The case scenarios are followed by questions about wheth-
er the participants have encountered such situations and, if
so, about how they handled them, or, if not, would handle
them. The remaining questions explored their personal atti-
tudes to NE and their knowledge about the possible side ef-
fects of certain neuroenhancers. These cases do not merely
capture medical aspects, but contain strong psychosocial
components with a kind of “moral appeal” to the (imagin-
ary) treating physician.
Sample
The questionnaire was designed to provide insights into
the attitudes, routine practice and knowledge that practising
physicians have of NE. Psychiatry and general practice
were chosen as the specialities which would have the
largest number of requests for neuroenhancers, as it is with-
in these specialities that Ritalin© (methylphenidate), a key
substance in the neuroenhancement debate, is mostly pre-
scribed [15]. Differences that could be correlated to gender,
speciality, clinical experience and language (German/
French) were of interest to the analysis. As requested by
the working group “Human Enhancement” of the Swiss
Academies of Sciences, which had commissioned the
study, the sample size was constructed with an equal dis-
tribution of all independent variables in order to facilitate
such comparisons and at the same time keep it as small as
possible. According to Bortz the preconditions of a vari-
ance analysis, like a normal distribution or the demand
of a homogeneous sample variance, can be neglected if
the subgroups contain more than ten members [16]. The
sample was defined in such a way as to include 100 persons
for each of the 16 combinations of gender (male, female),
specialist training (psychiatrist, GP and others), number
of working years (1–10, >10) and language (German,
French).
The survey was conducted between July and October 2011.
The questionnaire was sent out twice to 1600 Swiss prac-
tising physicians in the fields of psychiatry and general
practice/internal medicine. Addresses were obtained
through the Swiss Medical Association (Foederatio
Medicorum Helveticorum). With the second mailing, a
book voucher (20 CHF) was offered to those considering
participation in the study. A total of 800 of the addressees
were in the French part of Switzerland, while the other half
were located in the German-speaking part of Switzerland.
Due to relocation the number of persons who were reached
by mailing was reduced to 1589.
To eliminate double participation, a specific code was as-
signed to each participant, containing the first two letters of
their first and last names and their date of birth.
Analysis
Analyses were performed using SPSS version 19 for Mac.
We used univariate descriptive statistics to examine the
distribution for the items of each question. Next to that
were cross tables generated to identify the responses of the
physicians in more than one questionnaire. Pearson’s chi-
square was performed to test if the distributions among the
items were significantly different or, in relation to cross
tables, whether there was a relationship between two cat-
egorical variables (p <0.05). Cramer’s V was performed
to test the strength of association between two categorical
variables [17]. Subgroup analyses including Pearson’s chi-
square revealed if different responses were given according
to language (German/French), gender, speciality (psychi-
atry/general practice) and work experience (0–10 years /
>10 years).
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Results
A total of 393 questionnaires were returned (response rate
24.7%). 14 questionnaires had to be removed either be-
cause of the large amount of missing values (n = 4) or
because they were likely to have been sent in twice by
participants after the reminder (n = 10), leaving 379 ques-
tionnaires for the analysis (23.9%).
In the sample, 196 persons (52.1%) were male and 180
(47.9%) were female (nTotal = 376). The average year of
birth was 1953, with a range from 1942–1979. After the
first mailing, 155 questionnaires from German speakers
and 99 questionnaires from French speakers were returned
(67.0%; nTotal = 379). After the second mailing, an addition-
al 64 German and 61 French questionnaires were received.
Of these 125 persons who responded to the second mailing,
62 asked for the book voucher. This means that only half
of the participants (49.6%) to whom a book voucher was
offered took advantage of this offer.
In the sample, 208 persons specialised in “psychiatry and
psychotherapy”, 116 in “general medicine”, 65 in “internal
medicine” and a total of four persons had another speciality
title. A total of 19 persons specialised in two fields (nTotal
= 374). On average, participants had been working for 14.8
years in private practice (standard deviation: 9.7, nTotal =
362). The work environment was ‘rather rural’ for 32.7%
of the physicians and “rather urban” for 67.3% (nTotal =
370).
Knowledge of term and immediate response
Regarding the question “Do you know the term neuroen-
hancement?”, the majority of the respondents chose the an-
swer “no” (68.9%, nTotal = 376). The term “brain doping”
was better known among the participants and 53.6% of
the respondents indicated that they knew this term (nTotal =
371).
Table 1 shows the responses of participants confronted with
five statements about media reports on the increasing use of
performance-enhancing products among students and em-
ployees.
All five statements were chosen by more than 50% of the
sample. However, only eight of the participants affirmed all
five statements and relatively high values were documen-
ted in the category “undecided”.
Concepts of disease and treatment
When asked which criteria participants would use for de-
termining whether a dysfunction should be considered a
disease, “subjective suffering” was the most frequently
chosen criterion, followed by “negative consequences for
everyday ability to work” (table 2).
When asked how they would decide if a patient asked for
a prescription without an indication, the majority of the
participants (67.0%, n = 250; nTotal = 373) chose the an-
swer: “In general, I do not prescribe anything without an
indication. However, if subjective suffering is strong and
the patient wants to try whatever is possible, I might pre-
scribe something without a clear indication. This depends
on the substance and its contraindications and undesired
side effects.” A total of 28.4% of the participants (n =
106) answered: “Without indication I do not prescribe any-
thing.” Only a minority of the participants (4.6%, n = 17)
chose to reply: “I inform the patient concerning the pos-
sible risks of a desired drug and when she/he still wants it,
she/he should be free to try it.”
In the question about which medication participants would
prescribe without a clear indication, in response to a pa-
tient’s request, antidepressants were chosen from a list with
11 items by 13.3%, ranking fifth after NSAIDs (21.6%),
Viagra (20.3%), laxatives (17.6%) and benzodiazepines
(13.6%). The other six options (neuroleptic drugs (5.5%),
antibiotics (4.9%), opioids (1.9%) and three potential neur-
oenhancers – anti-dementia drugs (5.0%), methylphenidate
(2.5%) and modafinil (2.0%)) – were only chosen by a
small minority.
The case scenarios
Participants were confronted with the four case scenarios
described above. The introduction of each scenario was
followed by questions about which substances they would
Table 1: Which of the following statements come(s) closest to your own spontaneous reaction to the increasing use of performance enhancing drugs (multiple answers
possible)?
Yes, n (%) No, n (%) Undecided, n (%) nTotal
Hardly surprising that this is happening when demands and
competitive pressure continue to rise.
228 (62.5) 66 (18.1) 71 (19.5) 365
One should put a stop to these things. 183 (51.8) 57 (16.1) 113 (32.0) 353
Everybody is responsible for his/her own actions. 212 (58.6) 68 (18.8) 82 (22.7) 362
People have always tried to improve their performance. Coffee and
Red Bull are already around, it’s just that the range of possibilities
is increasing.
234 (65.0) 62 (17.2) 64 (17.8) 360
This is as wrong as doping in sports. 194 (53.7) 90 (24.9) 77 (21.3) 361
The highest value for each criterion is in bold letters. The numbers of the three answer categories differ significantly for all five reactions (p = 0.000).
Table 2: When you have to decide whether a dysfunction has disease value – what criteria are decisive for you (multiple answers possible)?
Yes, n (%) No, n (%) Sometimes, n (%) nTotal
Subjective suffering 317 (83.6) 8 (2.1) 50 (13.2) 375
Classification according to ICD / DSM) 165 (43.5) 93 (24.5) 100 (26.4) 358
Objectification with laboratory / visual methods 165 (43.5) 70 (18.5) 117 (30.9) 352
Negative consequences for everyday ability to work 290 (76.5) 11 (2.9) 65 (17.2) 366
The highest value for each criterion is in bold letters. The numbers of the three answer categories differ significantly for all four criteria (p = 0.000).
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prescribe (if any) and if they had received such requests in
their clinical practice.
As answers to the first question, about how participants
would act, four statements were offered (table 3). The state-
ment – “I would only prescribe drugs if psychotherapeutic
methods or comparable measures were not helpful enough”
– was the most popular overall. It was endorsed by most
of the participants for the third case scenario concerning
the shy woman and had least support in the case of the
renowned scientist asking for modafinil.
The statement: “I would prescribe a drug like Ritalin©, Mo-
dasomil©, antidepressants or anti-dementia drugs” was re-
jected by the majority of participants. However about one
third would hand out a prescription to the shy woman and
about a quarter to the single mother. Opinions were di-
vided about the statement; “I principally prescribe no drugs
in such situations”; it had least support in the case of the
single mother and the shy woman. The statement – “I do
not prescribe drugs in such situations, but refer to the pos-
sibility that the patient could consult some of my other col-
leagues or order via the Internet” – was overwhelmingly re-
jected by participants.
Most of the participants who would prescribe a drug in the
first scenario chose beta blockers (table 4), followed by an-
tidepressants and Ritalin© (methylphenidate). In the second
and third case scenarios, the majority chose antidepress-
ants. Modasomil© (modafinil) was selected by most of the
participants who would prescribe a drug in the fourth case
scenario. Overall, antidepressants were by far the most fre-
quently chosen drugs.
The next question turned from hypothetical questions to an
exploration of whether participants had in fact been con-
fronted with requests for enhancing products in their clin-
ical practice (table 5).
Whereas the “student” and the “shy woman” had been en-
countered by about half of participants, slightly fewer par-
ticipants had been confronted with the single mother case
and only about one fifth with the renowned scientist scen-
ario. 10.0% of the participants (n = 32) knew all scenarios,
in contrast to 19.8% who had not experienced any of them
(n = 63). The subgroup analysis according to work envir-
onments showed that the “shy woman” scenario had been
experienced by 23.7% of participants with a “rather rural”
surrounding, compared to 76.3% of those practising in a
“rather urban” setting (χ2(n = 333) = 13.911, p = 0.000).
This association between experience of the third scenario
and the environment is small (Cramer’s V = 0.2). The fre-
quency of requests was reported to be rather low, in most
cases 1–2 times per year for scenario 1–3 and “very rarely”
for scenario 4. 80.2% of the participants have experienced
at least one of the four case scenarios.
Personal attitudes
In terms of their personal attitudes towards NE, the major-
ity of participants were unsure if they would count them-
selves among those who principally oppose NE. At the
same time, half of the sample would consider the decision
for or against NE in the light of specific circumstances.
Less than 10% would embrace a consumer model, with
medical decisions guided by patient preferences (table 6).
In order to reach a better understanding of physicians’ de-
cisions for or against prescribing performance-enhancing
drugs, participants were confronted with different possible
criteria (table 7). The criteria were developed from prepar-
atory interviews with physicians.
The data in table 7 show that only the first three statements
on (1.) subjective suffering, (2.) the time-limited use of
Table 3: How would you react to a request for the prescription of a neuroenhancing substance?
Prescription Only if no therapeutic
alternative
No prescription Referral
Scenario 1: student 49 (15.3) 180 (54.4) 161 (49.2) 24 (7.8)
Scenario 2: single mother 83 (25.6) 176 (52.9) 137 (41.4) 14 (4.5)
Scenario 3: shy woman 107 (32.7) 244 (70.1) 88 (26.8) 19 (6.1)
Scenario 4: renowned scientist 54 (16.5) 52 (16.1) 193 (54.1) 35 (10.7)
The possible answers were “yes” and “no”; the table contains the values for the answer “yes”. nTotal ranges between 307 and 357 due to missing values.
Table 4: In case of drug prescription in the last question: which of the following substances would you prescribe in the described situation (multiple answers possible)?
Ritalin©
(methylphenidate)
Modasomil©
(modafinil)
Antidepressants Anti-
dementia
drugs
Beta
blockers
nTotal
Scenario 1: student 21 (11.7%) 5 (2.9%) 23 (12.7%) 1 (0.6%) 56 (29.6%) 205
Scenario 2: single mother 6 (3.4%) 1 (0.6%) 72 (37.3%) 1 (0.6%) 13 (7.5%) 206
Scenario 3: shy woman 3 (1.4%) 1 (0.5%) 110 (43.8%) 1 (0.5%) 17 (7.8%) 273
Scenario 4: renowned scientist 6 (8.6%) 24 (32.4%) 7 (9.9%) 1 (1.4%) 5 (7.1%) 89
The highest value is marked for each scenario. The column “nTotal” refers to all participants who had indicated in the previous question that they would prescribe a drug.
Table 5: Do you know of such requests from your own work?
Yes, n (%) No, n (%) nTotal p-value
Scenario 1: student 200 (53.5) 174 (46.5) 374 0.179
Scenario 2: single mother 156 (42.0) 215 (58.0) 371 0.002**
Scenario 3: shy woman 180 (52.9) 160 (47.1) 340 0.278
Scenario 4: renowned scientist 75 (21.7) 270 (78.3) 345 0.000***
The p-values of the χ2–test are noted in the last column.
*(0.01 ≤ p < 0.05); **(0.001 ≤ p < 0.01); ***(p <0.001). If the values differ significantly (p <0.05), the higher value is in bold letters.
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the drug and (3.) avoiding the development of something
worse were relevant for the majority of participants.
Finally, participants were asked to consider three state-
ments on NE (table 8). The majority considered the state-
ment that NE is a matter of individual conscience as fairly
or completely right. About a quarter were uncertain if NE
should become an integral part of medicine, with the re-
mainder agreeing or disagreeing in equal measure. Addi-
tionally, the majority thought that physicians’ public image
and trust would suffer if they moved away from the core
business of treating sick people.
Subgroup analyses according to language (German/
French), gender, speciality title (psychiatry/general prac-
tice) and work experience (0–10 years / >10 years) revealed
some differences (χ 2-Test with a p-value <0.05) regarding
the participants’ personal attitudes. For example, French-
speaking participants rated the criterion of subjective suf-
fering for prescribing neuroenhancers higher (item 1 of
table 7; p = 0.012, Cramer’s V = 0.14), while German
speakers and general practitioners gave more weight to the
importance and value of the reason for the request to en-
hance (item 5 of table 7; p = 0.000, Cramer’s V = 0.32).
Women were more concerned about an erosion of patient
trust (third statement of table 8; p = 0.011, Cramer’s V =
0.19).
At the end of the questionnaire, the physicians were asked
to select possible side effects to healthy people from an-
tidepressants, Ginkgo, methylphenidate (Ritalin©), anti-de-
mentia drugs and modafinil (Modasomil©) from a list;
(nTotal = 379). The two most frequently chosen answers
were: for antidepressants, nervousness/sleep disorders
(64.1%) and liver dysfunction (41.4%); for Gingko, none
(39.3%) and nervousness/sleep disorders (7.1%); for
methylphenidate (Ritalin©), nervousness/sleep disorders
(63.9%) and addiction (47.8%); for anti-dementia drugs,
nervousness/sleep disorders (18.2%) and liver dysfunction
(15.3%); for modafinil (Modasomil©), nervousness/sleep
disorders (22.2%) and arrhythmia (11.6%). The percentage
of those who did not choose any of the answers were
12.9% for antidepressants, and 43.0% for Gingko, 26.1%
for methylphenidate (Ritalin©), 63.1% for anti-dementia
drugs, and 68.3% for modafinil (Modasomil©).
Table 6: Personal attitude.
I agree,
n (%)
Undecided,
n (%)
I do not agree,
n (%)
nTotal p-value
As a physician, I refuse NE and would never prescribe such
substances.
108 (30.6) 145 (41.1) 100 (28.3) 353 0.007**
A decision for or against NE is context-dependent: I do not
categorically say no.
171 (49.0) 87 (24.9) 91 (26.1) 349 0.000***
When the patient is informed about the side effects and risks of the
desired drugs but still wants it, I respect this decision and prescribe
the drug.
33 (9.6) 94 (27.3) 217 (63.1) 344 0.000***
The p-values of the χ2–test are written in the last column.
*(0.01 ≤ p < 0.05); **(0.001 ≤ p < 0.01); ***(p <0.001). If the values differ significantly (p <0.05), the higher value is in bold letters.
Table 7: Which criteria influence your decision regarding the prescription of drugs in the different scenarios (multiple answers possible)?
Yes, n (%) No, n (%) nTotal p-value
The subjective suffering is intense. 294 (88.3) 39 (11.7) 333 0.000***
Rather for temporary use than for an undefined time span. 275 (82.8) 57 (17.2) 332 0.000***
To avoid a development that would be worse. 233 (75.6) 75 (24.4) 308 0.000***
When the person concerned did not provoke the situation she or he
is in.
80 (26.0) 228 (74.0) 308 0.000***
Whether the goal is obviously important and valuable or does also
benefit others.
90 (30.9) 201 (69.1) 291 0.000***
When it is clear that the person concerned tried hard enough to
reach the goal through his or her own efforts.
144 (46.5) 166 (53.5) 310 0.211
The p-values of the χ2–test are written in the last column.
*(0.01 ≤ p < 0.05); **(0.001 ≤ p < 0.01); ***(p <0.001). If the values differ significantly (p <0.05), the higher value is in bold letters.
Table 8: Please evaluate the following statements.
Statements Completely
wrong, n (%)
Fairly wrong,
n (%)
Undecided,
n (%)
Fairly right,
n (%)
Completely right,
n (%)
Every physician should decide for her-/ himself, whether she/he
wants to practice NE or not.
29 (7.9) 75 (20.4) 63 (17.2) 110 (30.0) 90
(24.5)
Neuroenhancement measures are a reality. Given this fact they
should become part of medical practice for the benefit of those who
wish to use them. This way the assessment and surveillance of
risks and undesired side effects can be guaranteed.
43 (12.1) 89 (25.1) 83 (23.4) 99 (27.9) 41 (11.5)
The public perception of physicians will be damaged and trust of
patients decrease if physicians move away from the core activity of
treating disease.
14 (3.9) 58 (16.0) 56 (15.5) 156 (43.1) 78 (21.5)
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Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 8
Discussion
Participants’ familiarity with the term and experience
of requests for NE
More than two-thirds of responding general physicians and
psychiatrists did not know the term “neuroenhancement”.
More than half had not heard of “brain doping”. This is
surprising considering that the topic is extensively dis-
cussed in the public press nowadays. However, when the
four case scenarios were described, more than 50% had
had experience of situations similar to those of the student
or the shy woman in their own medical practice, followed
in frequency by the overburdened single mother (42.0%)
and the exhausted scientist (21.7%; table 5). This finding
shows that many participants may not be very familiar with
the public discussion of the phenomenon, but can identify
comparable situations from their own practice. A signific-
ant number of physicians are confronted “very rarely” or
up to twice a year with such requests and only a minority
of the sample have patients who ask for cognitive en-
hancement weekly or monthly. Not surprisingly, certain re-
quests for NE are more frequent in a “rather urban” set-
ting (76.3%) in comparison to a “rather rural” one (23.7%),
which might be due to a more competitive environment,
higher expectations regarding cognitive and psychosocial
functioning in urban workplaces and easier access to in-
formation about neuroenhancers.
Attitudes towards NE measures
It is interesting to note that although almost half of the par-
ticipants declared they would as a matter of principle not
prescribe any drugs in cases such as the case scenarios,
between 15 and 33% would have prescribed a drug like
Ritalin© (methylphenidate), Modasomil© (modafinil), anti-
depressants or anti-dementia drugs. In fact, in the absence
of a therapeutic alternative, most respondents would pre-
scribe a drug, except for the case of the jet-lagged scientist.
Overall, antidepressants were mentioned most frequently
as the substances that would have been prescribed. There
may be less hesitation to prescribe if physicians have long-
standing experience with a drug and if the case is similar to
a condition that can be classified as a disease, such as so-
cial phobia in the case of the shy woman. The other case
scenarios – the student who did not prepare in time for his
exam, the exhausted mother and the jet-lagged scientist –
are all rather far removed from a pathological diagnosis.
Most participants (67%) had a rather pragmatic attitude
towards NE; although in general they do not prescribe
without an indication, they would consider doing so if there
were no therapeutic alternatives, the drug was fairly safe,
and if the patient suffered considerably and insisted on the
drug. The study of Banjo et al. [12] showed that the safety
of cognitive enhancers was also a main concern for physi-
cians in Canada and the USA. In our study, 28% answered
– in accordance with the professional guidelines – that they
do not prescribe drugs without an indication. A small, but
significant minority (5%) espoused a clearly liberal point
of view, prescribing drugs at the request of informed pa-
tients.
Yet participants are somewhat ambivalent in dealing with
the issue of NE. When asked if they would personally sub-
scribe to a categorical refusal of NE, 41% were undecided
(table 6). This ambivalence already becomes apparent in
the beginning of the questionnaire, when participants were
asked about their spontaneous reactions to performance-
enhancing drugs. There is a rather constant approval rate
of more than 50% to very different statements, such as
“neuroenhancement has always been around”, or “this is as
wrong as doping in sports”, or “everyone is responsible for
his/her own actions” (table 1).
There is also some uncertainty and disagreement as to how
the medical profession should position itself with a view
to NE. Most participants would consider NE as a matter of
a physician’s individual conscience. Nearly two thirds also
agree that the public perception of physicians might suf-
fer if medicine’s core business moves away from treating
sick people. However, opinions are divided on the issue of
whether NE should be considered a reality and as such be-
come part of medical practice for the benefit of those who
wish to use them. Answers show a distribution over the
whole spectrum from “completely wrong” to “completely
right” with nearly one fourth (23.4%) of participants “un-
decided” (table 8).
The ambivalence and uncertainty is in line with other sur-
veys. The main concern of the survey in the US [4] and the
study carried out in the US and in Canada [12] was about
possible side effects and a majority of the participants in
the study of Banjo et al. shared a rather “conservative”
view on enhancement, expressing scepticism about the use
of modern technologies to produce above normal human
capabilities, and being worried about their proper role as
physicians. The study of Hotze et al. [4] also showed a
similar constellation to the one in our study, with parti-
cipants espousing a rather pragmatic approach to enhance-
ment measures, accompanied by concerns about undesir-
able side effects. However, most of the physicians in the
US study think that safe and efficient NEPs should be
available, although they should not be reimbursed by insur-
ance companies [4]. The survey done in Sweden revealed
that participants had more negative attitude toward the use
of neuroenhancers (117 physicians and 520 randomly se-
lected individuals) [11].
Understanding of disease criteria and justification for
neuroenhancement measures
The openness of many participants to consider prescribing
in the absence of a medical indication fits with their appre-
ciation of subjective suffering and malfunctioning in daily
life as criteria for disease (table 2). The two medical sub-
disciplines of general medicine and psychiatry, which were
included in this study, have a reputation for taking the pa-
tient’s subjective perception into account and not reducing
medical diagnosis to mere objective criteria. Although the
acknowledgement of subjective parameters has long been
called for, an emphasis on individual well-being might, on
the other hand, lead to a kind of wish-fulfilling medicine
that blurs the line between medical need and individual
desire. From a subjectivist understanding of disease, en-
hancement interventions are not necessarily seen as “non-
therapeutic interventions”. If subjective suffering counts as
a criterion for disease, enhancement interventions can be
considered as a kind of therapy. This also explains why
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many participants do not simply follow medical indica-
tions, which are mostly defined according to “objective”
disease criteria, but consider the prescription of a drug out-
side of a clear medical indication as a context-dependent
decision.
When asked which criteria influenced their decision to pre-
scribe or not in cases such as the four case scenarios, most
respondents chose subjective suffering (table 7). The tem-
porariness of the measure and avoiding the development of
something worse were also considered important criteria.
In contrast, a majority of the participants disapproved of
criteria which involved a moral evaluation of the patients’
intentions and goals by “When the person concerned did
not provoke the situation she or he is in”, “Whether the goal
is obviously important and valuable or also benefits oth-
ers”, or “When … the person concerned tried hard enough
…”. One can conclude from these data that the avoidance
of harm (subjective suffering, worse consequences) is seen
as a legitimate aim of enhancement measures, but that this
is seen largely independently from a moral evaluation of
the person concerned.
The importance of the medical indication in
Switzerland
Like in many other countries, it is the standard case of
pharmacological treatment in Switzerland that physicians
should prescribe drugs according to the related indication.
Nevertheless, in some instances it is also expected or even
obligatory to prescribe drugs off-label. However, this is not
the case regarding the prescriptions which were described
in the present study, because the questionnaire clearly re-
ferred to healthy individuals who wanted to improve their
cognitive performance or wanted to manage non-health re-
lated problems. An exception may be the scenario with the
shy woman. Her state might possibly also be described as a
mild personality disorder or phobia. In general, drugs pre-
scribed for the case scenarios described in our study should
not have been reimbursed by Swiss health insurance [18].
The Swiss Social Insurance Law (ATSG) defines in Art. 3
disease as “every impairment of physical or mental health,
which is not the consequence of an accident, requires med-
ical examination or treatment or is followed by inability
to work” [19]. The medicine compendium of Switzerland
names as indications for Ritalin© (methylphenidate) hy-
perkinetic behaviour dysfunctions, attention-deficit hyper-
activity disorder and narcolepsy and adds that “Ritalin© is
indicated as a part of a comprehensive therapy programme,
which should typically comprise of psychological, educa-
tional and social treatment measures” [20]. The informa-
tion for modafinil in Switzerland (Modasomil©) contains
the following indications: excessive somnolence in connec-
tion with narcolepsy with and without cataplexy. It adds
that “a treatment with Modasomil© should only be car-
ried out after careful diagnostic investigation by a neuro-
logist/pulmonologist” [21]. The conditions described in the
case scenarios would not have fallen under these categor-
ies, nor would there have been an indication for anti-de-
mentia drugs.
Limitations of the study
Regarding self-selection bias in the group of the study re-
spondents, there are two potential scenarios. First, physi-
cians who are particularly critical with regard to cognitive
enhancement practices may have been especially interested
in participating in the survey and are thus overrepresented.
Second, physicians who are very much in favour of such
practices may have been especially interested in the study.
As a consequence, individuals with a positive attitude to
such practices might be overrepresented. However, both
scenarios do not seem very likely from our point of view,
given the coherence with results of previous studies: simil-
arly to the study of Hotze et al. [4], we found a high preval-
ence of “mixed attitudes”, i.e. an ambivalent evaluation of
cognitive enhancement practices in our study sample.
Furthermore, bias due to socially desired response behavior
is rather improbable not only because of the anonymity of
the questionnaire but also because some responses could be
considered to be the socially undesirable response from an
ethical or even from a legal point of view (for example the
prescription of costly drugs without a medical indication).
Another source of potential bias is that our questionnaire
contains assumptions about an increasing use of neuroen-
hancers; this is not a proven fact, although the rising figures
for the use of certain drugs, such as methylphenidate (Rital-
in©) suggest that they are used beyond clear medical indic-
ations [15]. Finally, another limitation of the study could be
the descriptions of the four case scenarios. They could only
be briefly described conveying a schematic impression of
the underlying clinical problem to the participants. Apart
from the case of the shy woman, the cases are clearly non-
pathological.
Conclusions
Our study shows that there is considerable openness to NE
among Swiss psychiatrists and general practitioners. This is
not an uncritical acceptance, however, but depends on the
expected alleviation of suffering, the lack of therapeutic al-
ternatives, the safety of the drug and the preferences of the
individual. Objective criteria for disease are secondary in
these considerations. It might be, however, that a proximity
to recognised diseases, such as social phobia, or the famili-
arity with a drug fosters acceptance of a NE measure.
The lack of knowledge of the terms “neuroenhancement”
or “brain doping”, the heterogeneity of spontaneous re-
sponses to different moral statements on NE and the un-
certainty and ambivalence present in the replies to some
items indicate that physicians might profit from a more
systematic ethical debate on these issues. Given the some-
times rather diverging positions and increasing prescription
rates of drugs such as methylphenidate (Ritalin©) that can
be used as neuroenhancers, a debate within the profession
might also be clarifying and help define individual mem-
bers’ views. Finally, the prescription of drugs for non-
therapeutic purposes is a phenomenon that deserves further
analysis and research. There is a need for an ethical and
legal clarification regarding the justification of drug pre-
scriptions, which should be addressed by the respective
professional societies.
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